SCHEMBL10117151

SCHEMBL10117151

CCCc1ccc(NC(=O)CC)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.60
HDAC3 O15379 1/20 0.58
HDAC4 P56524 1/20 0.58
HDAC1 Q13547 1/20 0.58
HDAC7 Q8WUI4 1/20 0.58
HDAC2 Q92769 1/20 0.58
HDAC10 Q969S8 1/20 0.58
HDAC11 Q96DB2 1/20 0.58
HDAC8 Q9BY41 1/20 0.58
HDAC6 Q9UBN7 1/20 0.58
HDAC9 Q9UKV0 1/20 0.58
HDAC5 Q9UQL6 1/20 0.58
GAA P10253 2/20 0.58
ATM Q13315 1/20 0.58
MAPT P10636 1/20 0.58
RAB9A P51151 4/20 0.57
HPGD P15428 3/20 0.57
NPC1 O15118 3/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
ALDH1A1 P00352 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9312694 0.90 POLB (0.67) POLBHDAC3HDAC4HDAC1HDAC7
SCHEMBL2619349 0.89 POLB (0.76) POLBHDAC3HDAC4HDAC1HDAC7
SCHEMBL8866798 0.87 POLB (0.57) POLBHDAC3HDAC4HDAC1HDAC7
SCHEMBL8867604 0.87 POLB (0.57) POLBHDAC3HDAC4HDAC1HDAC7
SCHEMBL8817395 0.87 HDAC3 (0.76) POLBHDAC3HDAC4HDAC1HDAC7
SCHEMBL13989319 0.85 GAA (0.73) POLBGAAATMMAPTRAB9A
SCHEMBL17874906 0.85 POLB (0.61) POLBHDAC3HDAC4HDAC1HDAC7
SCHEMBL10616270 0.85 POLB (0.57) POLBHDAC3HDAC4HDAC1HDAC7
SCHEMBL16691055 0.85 GAA (0.69) POLBHDAC3HDAC4HDAC1HDAC7
SCHEMBL5551950 0.85 POLB (0.81) POLBHDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2831264-B1 BACTERIAL IMAGING AGENTS AND METHODS OF USING SAME VISEN MEDICAL INC (US) 2019-07-10 EP disclosed
US-9375493-B2 Bacterial imaging agents and methods of using same VISEN MEDICAL, INC. (US) 2016-06-28 US disclosed
US-20120165316-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-28 US disclosed
US-20120094997-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-04-19 US disclosed
WO-2012045114-A1 AGENTS AND METHODS FOR TREATING HEMATOLOGIC CONDITIONS THE UNIVERSITY OF QUEENSLAND (AU) 2012-04-12 WO disclosed
US-20110251184-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-10-13 US disclosed
US-20110213003-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
US-20090246211-A1 Molecular constructs suitable for targeted conjugates TAPESTRY PHARMACEUTICALS, INC. 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094997-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC5 POLB 578/4885HDAC3 5/4885HDAC4 8/4885
US-20120165316-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC5, HDAC1 POLB 1000/4885HDAC3 4/4885HDAC4 9/4885
US-20110251184-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, H1-3 POLB 303/4885HDAC3 12/4885HDAC4 13/4885
US-20110213003-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC3 POLB 467/4885HDAC3 3/4885HDAC4 7/4885
US-20090246211-A1 Molecular constructs suitable for targeted conjugates MRPL21, QSOX1, MLX POLB 3551/4885HDAC3 3487/4885HDAC4 4533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.